


Lonza

Restated Financials 2020



Restated Full-Year 2020 Financial Information as of 31 December 2020

Restated Full-Year 2020

Million CHF	Pharma, Biotech & Nutrition	Corporate	Group (continuing)	Specialty Ingredients ¹	Group (total)
Net Sales	4'472	36	4'508	1'677	6'185
CORE EBITDA	1'414	(35)	1'379	317	1'696
Margin in %	31.6%		30.6%	18.9%	27.4%
EBIT			901	195	1'096
EBITDA			1'378	278	1'656

Restated for revised Alternative Performance Measures definitions

Reported Full-Year 2020

Million CHF	Pharma, Biotech & Nutrition	Corporate	Group (continuing)	Specialty Ingredients ¹	Group (total)
Net Sales	4'472	36	4'508	1'677	6'185
CORE EBITDA	1'436	(30)	1'406	322	1'728
Margin in %	32.1%		31.2%	19.2%	27.9%
EBIT			901	195	1'096
EBITDA			1'378	278	1'656

Restatement Impacts Full-Year 2020²

Million CHF	Pharma, Biotech & Nutrition	Corporate	Group (continuing)	Specialty Ingredients ¹	Group (total)
Net Sales	0	0	0	0	0
CORE EBITDA	(22)	(5)	(27)	(5)	(32)

Reorganizational Change – Split of the Pharma, Biotech & Nutrition Segment Into Four Divisions (Based on Restated Results) / Full-Year 2020

Million CHF	Small Molecules	Biologics	Cell & Gene ³	Capsules & Health Ingredients	Pharma, Biotech & Nutrition
Net Sales	692	2'146	481	1'153	4'472
CORE EBITDA	192	831	13	378	1'414
Margin in %	27.7%	38.7%	2.7%	32.8%	31.6%

Reconciliation of EBITDA to CORE EBITDA (Continuing Business)

Million CHF	2020 restated	2020 as reported
Earnings before interest, taxes and depreciation (EBITDA)	1'378	1'378
Restructuring costs	0	22
(Income) / expense resulting from acquisition and divestitures	(7)	(5)
Environmental-related expenses	8	11
CORE EBITDA	1'379	1'406

1 Lonza Specialty Ingredients business classified as Discontinued Operations

2 Restatement impacts resulted from new definition of Alternative Performance Measures only. At 31 December 2020, Specialty Ingredients was reported as Discontinued Operations already

3 Cell & Gene division includes Cell & Gene Technologies and Bioscience businesses

Restated Half-Year 2020 Financial Information as of 30 June 2020

Restated Half-Year 2020

Million CHF	Pharma, Biotech & Nutrition	Corporate	Group (continuing)	Specialty Ingredients ¹	Group (total)
Net Sales	2'226	17	2'243	831	3'074
CORE EBITDA	754	(5)	749	136	885
Margin in %	33.9%		33.4%	16.4%	28.8%
EBIT			531	87	618
EBITDA			750	136	886

Restated for LSI Discontinued Operations & revised Alternative Performance Measures definitions

Reported Half-Year 2020

Million CHF	Pharma, Biotech & Nutrition	Corporate	Group (continuing) ²	Specialty Ingredients ¹	Group (total)
Net Sales	2'226	29	Lonza's HY 2020 reporting did not yet differentiate between continuing and discontinued operations	819	3'074
CORE EBITDA	760	(28)		161	893
Margin in %	34.1%			19.7%	29.1%
EBIT					618
EBITDA					886

Restatement Impacts Half-Year 2020

Impacts from classification of Specialty Ingredients as Discontinued Operations

Million CHF	Pharma, Biotech & Nutrition	Corporate	Group (continuing)	Specialty Ingredients ¹	Group (total)
Net Sales	0	(12)	(12)	12	0
CORE EBITDA	0	22	22	(22)	0

Impacts from new definition of Alternative Performance Measures

Million CHF	Pharma, Biotech & Nutrition	Corporate	Group (continuing)	Specialty Ingredients ¹	Group (total)
Net Sales	0	0	0	0	0
CORE EBITDA	(6)	1	(5)	(3)	(8)

Reorganizational Change – Split of the Pharma, Biotech & Nutrition Segment Into Four Divisions (Based on Restated Results) / Half-Year 2020

Million CHF	Small Molecules	Biologics	Cell & Gene ³	Capsules & Health Ingredients	Pharma, Biotech & Nutrition
Net Sales	315	1'100	227	584	2'226
CORE EBITDA	78	461	(2)	217	754
Margin in %	24.8%	41.9%	-0.9%	37.2%	33.9%

Reconciliation of EBITDA to CORE EBITDA (Continuing Business)

Million CHF	2020 restated
Earnings before interest, taxes and depreciation (EBITDA)	750
Restructuring costs	0
(Income) / expense resulting from acquisition and divestitures	(1)
Environmental-related expenses	0
CORE EBITDA	749

1 Lonza Specialty Ingredients business classified as Discontinued Operations

2 Historically Specialty Ingredients was reported as reportable segment as part of Lonza Group and was only presented as discontinued operations subsequent to the decision by Lonza's Board of Directors to divest this business in the 2nd half of 2020. As a consequence, Group Continuing Operations were not reported in the Half-Year Reporting 2020

3 Cell & Gene division includes Cell & Gene Technologies and Bioscience businesses

Updated Financial Reporting

The updated financial reporting provides further performance details at divisional level for investors. The main key performance indicators will include sales, CORE EBITDA margin and CAPEX. These figures will also be provided for the Group, alongside cash flow, ROIC, CORE EPS and Net Debt / CORE EBITDA. The new reporting steering model will change the consideration of non-CORE adjustments, through excluding the amortization of acquisition related intangibles as well as increasing the threshold for non-CORE adjustments to CHF 20 million per event. The comprehensive revised Alternative Performance Measures definitions and the reconciliation of all Alternative Performance Measures will be published with Half-Year Results 2021 on 23 July 2021.

Income Statement

Restated Condensed Consolidated Income Statement
for the Six Months Ended 30 June

Million CHF	2020 Lonza Group restated	2020 Lonza Group as reported
Sales	2'243	3'074
Cost of goods sold	(1'269)	(1'851)
Gross profit	974	1'223
Operating expenses	(443)	(605)
Result from operating activities (EBIT)¹	531	618
Net financial result	(44)	(50)
Share of loss from associates/joint ventures	(1)	(4)
Profit before income taxes	486	564
Income taxes	(44)	(86)
Profit from continuing operations	442	478
Profit / (loss) from discontinued operations, net of tax	36	0
Profit for the period	478	478
Attributable to:		
Equity holders of the parent	477	477
Non-controlling interests	1	1
Profit for the period	478	478
Earnings per share for profit from continuing operations attributable to equity holders of the parent		
Basic earnings per share – EPS basic (CHF)	5.94	6.42
Diluted earnings per share – EPS diluted (CHF)	5.91	6.39
Earnings per share for profit attributable to equity holders of the parent		
Basic earnings per share – EPS basic (CHF)	6.42	6.42
Diluted earnings per share – EPS diluted (CHF)	6.39	6.39

1 Result from operating activities (EBIT) excludes interest income and expenses as well as financial income and expenses that are not interest related and Lonza's share of profit/loss from associates and joint ventures

For publications and further information please contact:

Lonza Group Ltd

Muenchensteinerstrasse 38
4002 Basel, Switzerland
Tel + 41 61 316 81 11
www.lonza.com

Investor Relations

Tel + 41 61 316 85 40
investor.relations@lonza.com

Media / Corporate Communications

Tel + 41 61 316 87 98
media@lonza.com

Share Register

c/o Computershare Schweiz AG
P.O. Box
4601 Olten, Switzerland
Tel + 41 62 205 77 00
Fax + 41 62 205 77 90
share.register@computershare.ch

Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

© 2021 Lonza Ltd